Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 120

Similar articles for PubMed (Select 22527432)

1.

Lessons of leprosy: the emergence of TH17 cytokines during type II reactions (ENL) is teaching us about T-cell plasticity.

Martiniuk F, Giovinazzo J, Tan AU, Shahidullah R, Haslett P, Kaplan G, Levis WR.

J Drugs Dermatol. 2012 May;11(5):626-30.

2.

Effective treatment of erythema nodosum leprosum with thalidomide is associated with immune stimulation.

Haslett PA, Roche P, Butlin CR, Macdonald M, Shrestha N, Manandhar R, Lemaster J, Hawksworth R, Shah M, Lubinsky AS, Albert M, Worley J, Kaplan G.

J Infect Dis. 2005 Dec 15;192(12):2045-53. Epub 2005 Nov 10.

3.

[Pentoxifylline in the treatment of erythema nodosum leprosum: results of an open study].

de Carsalade GY, Achirafi A, Flageul B.

Acta Leprol. 2003;12(3):117-22. French.

PMID:
15040702
4.

Thalidomide in the treatment of leprosy.

Teo S, Resztak KE, Scheffler MA, Kook KA, Zeldis JB, Stirling DI, Thomas SD.

Microbes Infect. 2002 Sep;4(11):1193-202. Review.

PMID:
12361920
6.

Thalidomide's effectiveness in erythema nodosum leprosum is associated with a decrease in CD4+ cells in the peripheral blood.

Shannon EJ, Ejigu M, Haile-Mariam HS, Berhan TY, Tasesse G.

Lepr Rev. 1992 Mar;63(1):5-11.

PMID:
1569817
7.

The effect of antigen presenting cells on the cytokine profiles of stable and reactional lepromatous leprosy patients.

Nath I, Vemuri N, Reddi AL, Jain S, Brooks P, Colston MJ, Misra RS, Ramesh V.

Immunol Lett. 2000 Dec 1;75(1):69-76.

PMID:
11163869
8.

IgG antibody subclasses, tumor necrosis factor and IFN-gamma levels in patients with type II lepra reaction on thalidomide treatment.

Partida-Sanchez S, Favila-Castillo L, Pedraza-Sanchez S, Gomez-Melgar M, Saul A, Estrada-Parra S, Estrada-Garcia I.

Int Arch Allergy Immunol. 1998 May;116(1):60-6.

PMID:
9623511
9.

Erythema nodosum leprosum in Nepal: a retrospective study of clinical features and response to treatment with prednisolone or thalidomide.

Feuth M, Brandsma JW, Faber WR, Bhattarai B, Feuth T, Anderson AM.

Lepr Rev. 2008 Sep;79(3):254-69.

PMID:
19009975
10.

Effect of rhuIFN-gamma treatment in multibacillary leprosy patients.

Sampaio EP, Malta AM, Sarno EN, Kaplan G.

Int J Lepr Other Mycobact Dis. 1996 Sep;64(3):268-73.

PMID:
8862260
11.

Delayed-type hypersensitivity reactions followed by erythema nodosum leprosum.

Rea TH, Sieling PA.

Int J Lepr Other Mycobact Dis. 1998 Sep;66(3):316-27.

PMID:
9934358
12.

Double-blind trial of the efficacy of pentoxifylline vs thalidomide for the treatment of type II reaction in leprosy.

Sales AM, de Matos HJ, Nery JA, Duppre NC, Sampaio EP, Sarno EN.

Braz J Med Biol Res. 2007 Feb;40(2):243-8.

13.

[Thalidomide used by patients with erythema nodosum leprosum].

Valente Mdo S, Vieira JL.

Rev Soc Bras Med Trop. 2010 Mar-Apr;43(2):201-4. Portuguese.

14.

Thalidomide levels in patients with erythema nodosum leprosum.

Vieira JL, Valente Mdo S.

Ther Drug Monit. 2009 Oct;31(5):602-3. doi: 10.1097/FTD.0b013e3181b46c1e.

PMID:
19704404
15.
16.

CD4+ Th17 cells discriminate clinical types and constitute a third subset of non Th1, Non Th2 T cells in human leprosy.

Saini C, Ramesh V, Nath I.

PLoS Negl Trop Dis. 2013 Jul 25;7(7):e2338. doi: 10.1371/journal.pntd.0002338. Print 2013.

17.

Sequential erythema nodosum leprosum and reversal reaction with similar lesional cytokine mRNA patterns in a borderline leprosy patient.

Moraes MO, Sampaio EP, Nery JA, Saraiva BC, Alvarenga FB, Sarno EN.

Br J Dermatol. 2001 Jan;144(1):175-81.

PMID:
11167702
18.

The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum.

Sampaio EP, Kaplan G, Miranda A, Nery JA, Miguel CP, Viana SM, Sarno EN.

J Infect Dis. 1993 Aug;168(2):408-14.

PMID:
8335978
19.
20.

In vitro thalidomide does not interfere with the activation of complement by M. leprae.

Shannon EJ, Sandoval FG, Morales MJ.

J Drugs Dermatol. 2011 Mar;10(3):274-8.

PMID:
21369644
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk